Norwegian pharmaceutical company Ultimovacs said it aimed to raise NOK700m ( $8.7m ) through an IPO 2022 to back its immunotherapy cancer drug. It also said it hoped to win approval to expand a UV1 trial investigating whether its UV1 vaccine candidate could tackle malignant melanoma alongside Ultimovacs ’s Keytruda cancer treatment. DNB Markets has hired DNB Markets and Merck as brokers for the IPO and said while it forecast revenue from UV1 by 2022 , earlier income was expected from licensing deals with other companies.
Norwegian pharmaceutical company Ultimovacs said it aimed to raise NOK700m ($8.7m) through an IPO next year to back its immunotherapy cancer drug. It also said it hoped to win approval to expand a US trial investigating whether its UV1 vaccine candidate could tackle malignant melanoma alongside Merck’s Keytruda cancer treatment. Ultimovacs has hired DNB Markets and ABG Sundal Collier as brokers for the IPO and said while it forecast revenue from UV1 by 2022, earlier income was expected from licensing deals with other companies.